Lopinavir/Ritonavir/Combivir vs. Abacavir/Zidovudine/Lamivudine for Virologic Efficacy and the Prevention of Mother-to-Child HIV Transmission Among Breastfeeding Women With CD4 Counts Greater Than or Equal to 200 Cells/mm3 in Botswana.

Next Previous
Trial Profile

Lopinavir/Ritonavir/Combivir vs. Abacavir/Zidovudine/Lamivudine for Virologic Efficacy and the Prevention of Mother-to-Child HIV Transmission Among Breastfeeding Women With CD4 Counts Greater Than or Equal to 200 Cells/mm3 in Botswana.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2017

At a glance

  • Drugs Lamivudine/zidovudine/abacavir (Primary) ; Lopinavir/ritonavir (Primary) ; Lamivudine; Lamivudine/zidovudine; Nevirapine; Zidovudine
  • Indications HIV infections; HIV-1 infections; Pregnancy
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 25 Apr 2012 Actual end date changed from May 2009 to Sep 2010 as reported by ClinicalTrials.gov.
    • 02 Mar 2011 Infant and maternal mortality results presented at the 18th Conference on Retroviruses and Opportunistic Infections.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top